Growth hormone-releasing hormone analogue

CJC-1295 in Canada

Also known as CJC-1295 DAC · CJC-1295 without DAC · Modified GRF (1-29) · Mod GRF 1-29 · DAC:GRF · Tetrasubstituted GHRH (1-29)

CJC-1295 is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone, modified at four positions to resist enzymatic breakdown. It exists in two forms that share a name and little else: with a Drug Affinity Complex (DAC) that binds serum albumin and extends the half-life to about a week, and without it, where the half-life is measured in minutes. The DAC version was developed by ConjuChem in Montréal and reached Phase 2 before the programme stopped. Canada Peptides carries research-grade CJC-1295 with DAC, without DAC, and pre-mixed with ipamorelin, priced and shipped in CAD for laboratory and research use only.

Quick facts

Class: Synthetic GHRH(1-29) analogue; with DAC, an albumin-binding bioconjugate
Structure: 29 amino acids with D-Ala2, Gln8, Ala15 and Leu27 substitutions (~3,368 Da); DAC form adds a Lys30-linked maleimidopropionyl tag (~3,647 Da)
Half-life: With DAC: 5.8–8.1 days in humans. Without DAC: roughly 30 minutes
Route in research: Subcutaneous in human and animal studies
Cadence in research: With DAC: single doses, or weekly to fortnightly in trials. Without DAC: two to three times daily in applied research
Storage: Lyophilised: refrigerated, dark. Reconstituted: refrigerated, used within weeks
Status in Canada

CJC-1295 FAQ

Is CJC-1295 for sale in Canada?

Yes. Research-grade CJC-1295 is available in Canada from Canada Peptides with DAC, without DAC, and pre-mixed with ipamorelin, priced and shipped in CAD. It is supplied strictly for laboratory and research use, not for human consumption.

What is CJC-1295?

CJC-1295 is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone, with four substitutions that stop it being broken down within minutes. It stimulates the pituitary to release growth hormone through the GHRH receptor. It was developed by ConjuChem in Montréal in the early 2000s.

What is the difference between CJC-1295 with DAC and without DAC?

The Drug Affinity Complex is a chemical tag that binds the peptide to albumin in the blood, extending its half-life from about 30 minutes to about a week. With DAC produces a sustained rise in GH and IGF-1 from a single weekly dose; without DAC (Modified GRF 1-29) produces a short pulse and is dosed several times a day in applied research. Only the DAC form has been studied in humans.

What does the research on CJC-1295 actually show?

Human studies from 2006 showed that CJC-1295 with DAC raised GH two- to ten-fold and IGF-1 1.5- to three-fold for a week or more after a single dose, with pulsatile GH secretion preserved. The Phase 2 programme in HIV lipodystrophy was not completed. There is no published trial of either form for body composition, sleep, recovery or ageing.

What is the half-life of CJC-1295?

With DAC, 5.8 to 8.1 days in humans, because the peptide is covalently bound to albumin. Without DAC, roughly 30 minutes — about ten times longer than native GHRH but still short enough that the GH pulse it triggers is over within a couple of hours.

How was CJC-1295 dosed in studies?

The DAC form was given subcutaneously at 30 to 90 µg/kg as single doses, or 30 to 60 µg/kg weekly or fortnightly. The no-DAC form has no published human study. There is no validated human dose for any research purpose, and this page does not recommend one; the material sold here is for research use only.

What side effects does CJC-1295 research report?

Trials of the DAC form reported injection-site reactions, flushing, headache and, at higher doses, fluid retention and joint discomfort. A participant died during the ConjuChem Phase 2 programme; the death was not publicly attributed to the drug, but the programme ended and no long-term safety data exists. The FDA declined to permit CJC-1295 in compounded medicines in 2023.

Is CJC-1295 legal in Canada?

CJC-1295 is not a controlled substance in Canada, but it has no Health Canada approval for human use and no DIN. It may be sold for laboratory research, which is how it is sold here. It is prohibited for tested athletes under WADA's S2 category, which names it explicitly.

CJC-1295 in Canada

Quick facts

CJC-1295 — for sale in Canada

What is CJC-1295?

Evidence at a glance

Pharmacology

Identity and chemistry

Storage and stability

Research indications

Research protocols

Interactions and stacking in research

Reconstitution and handling

Side effects and safety signals

Regulatory status in Canada

Further reading

CJC-1295 FAQ

Research references